Stearoyl–coenzyme A desaturase enhances cell survival in human uterine leiomyoma
article
OA: gold
CC0
Abstract
OBJECTIVE: Stearoyl-CoA desaturase (SCD1) is an enzyme that catalyzes the conversion of saturated delta-9 fatty acids to monounsaturated fatty acids. SCD1 is highly expressed in various cancers and facilitates cancer cell survival, tumor growth, and metastasis. This study aimed to assess SCD1 expression and function in uterine leiomyoma and matched myometrial tissue and evaluate the impact of SCD1 inhibition on leiomyoma cell viability and apoptosis. DESIGN: Gene set enrichment analysis was performed to determine whether lipid metabolism pathways are dysregulated in leiomyoma. To assess the function of SCD1, primary leiomyoma and myometrial cells, as well as a CRISPR-engineered leiomyoma-relevant MED12 mutant human uterine smooth muscle (UtSM) cell line, were treated with SCD1 small interfering RNA or a small molecule inhibitor of SCD1, CAY10566. Cell viability and apoptosis assays, real-time quantitative polymerase chain reaction, and immunoblot analyses were performed to evaluate cell function in response to treatment. SUBJECTS: Leiomyoma and myometrial tissues were obtained from premenopausal individuals designated female at birth (n = 30) undergoing myomectomy or hysterectomy. EXPOSURE: SCD1 inhibition by small interfering RNA and CAY10566 treatment. MAIN OUTCOME MEASURES: Messenger RNA (mRNA) and protein levels and cell viability and apoptosis. RESULTS: Gene set enrichment analysis revealed that the cholesterol homeostasis pathway was significantly different in leiomyoma vs. adjacent myometrial tissues. Among the genes in this pathway, SCD1 mRNA levels were found to be significantly higher in leiomyoma than in matched myometrium. SCD1 inhibition by small interfering RNA or CAY10566 decreased antiapoptotic BCL2 mRNA and protein levels and cell viability in primary leiomyoma but not myometrial cells. SCD1 protein levels were significantly higher in the mutant MED12 UtSM cell line than in the wild-type MED12 UtSM cell line. CAY10566 treatment specifically decreased cell viability and increased apoptosis in mutant MED12 UtSM cells, with increased protein levels of cleaved caspase 3, cleaved PARP, and DDIT3 in mutant MED12 UtSM but not in wild-type MED12 UtSM cells. CONCLUSION: SCD1, an enzyme involved in lipid homeostasis, may play an important role in promoting leiomyoma growth and represents a novel target for the treatment of leiomyoma.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas 2023
- Omega‐3 fatty acids modulate the lipid profile, membrane architecture, and gene expression of leiomyoma cells 2018
- Preperitoneal Fat Thicknesses, Lipid Profile, and Oxidative Status in Women With Uterine Fibroids 2017
References (60)
- MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas via openalex
- Omega‐3 fatty acids modulate the lipid profile, membrane architecture, and gene expression of leiomyoma cells via openalex
- Preperitoneal Fat Thicknesses, Lipid Profile, and Oxidative Status in Women With Uterine Fibroids via openalex
- doi:10.1126/science.aaw5473 via openalex
- doi:10.1002/ana.25920 via openalex
- doi:10.1038/s41598-021-89859-0 via openalex
- doi:10.1016/j.celrep.2021.108927 via openalex
- doi:10.1038/s41586-021-03747-1 via openalex
- doi:10.1007/s12035-021-02695-1 via openalex
- doi:10.1158/0008-5472.can-21-4044 via openalex
- W4221136957 via openalex
- doi:10.3389/fsurg.2023.1151901 via openalex
- doi:10.1067/mob.2003.99 via openalex
- doi:10.1038/s41467-023-39684-y via openalex
- doi:10.1016/j.stemcr.2021.07.013 via openalex
- doi:10.1073/pnas.2203480119 via openalex
- doi:10.1038/s41591-021-01495-3 via openalex
- doi:10.1210/jc.2017-01585 via openalex
- doi:10.1016/j.jhepr.2021.100237 via openalex
- doi:10.1371/journal.pone.0033251 via openalex
- doi:10.1371/journal.pone.0166231 via openalex
- doi:10.1016/0014-4800(77)90035-1 via openalex
- doi:10.1186/s12967-018-1430-x via openalex
- doi:10.1158/1078-0432.ccr-12-3249 via openalex
- doi:10.18632/oncotarget.24304 via openalex
- doi:10.1146/annurev-biochem-061009-102430 via openalex
- doi:10.1111/jcmm.14114 via openalex
- doi:10.1371/journal.pone.0011394 via openalex
- doi:10.1210/en.2009-1225 via openalex
- doi:10.1016/j.ajog.2015.03.019 via openalex
- doi:10.1097/01.lab.0000017499.51216.3e via openalex
- doi:10.1002/humu.22612 via openalex
- doi:10.1016/j.bpobgyn.2015.11.016 via openalex
- doi:10.1016/j.molcel.2018.11.028 via openalex
- doi:10.1007/s10397-014-0842-8 via openalex
- doi:10.1194/jlr.m600299-jlr200 via openalex
- doi:10.1158/1541-7786.mcr-11-0126 via openalex
- doi:10.1172/jci81534 via openalex
- doi:10.1016/j.bbrc.2005.05.013 via openalex
- doi:10.1007/s11010-011-1211-9 via openalex
- doi:10.1016/j.bbalip.2017.07.009 via openalex
- doi:10.1016/s0002-9378(16)32480-2 via openalex
- doi:10.1210/jc.2014-2764 via openalex
- doi:10.1194/jlr.m700359-jlr200 via openalex
- doi:10.1371/journal.pone.0033823 via openalex
- doi:10.1056/nejmra1209993 via openalex
- doi:10.1126/science.1208930 via openalex
- doi:10.1016/j.biochi.2013.08.026 via openalex
- doi:10.1016/s0022-2275(20)33401-5 via openalex
- doi:10.1186/s40170-016-0146-8 via openalex
- doi:10.1007/s11010-018-3306-z via openalex
- doi:10.1152/ajpendo.90897.2008 via openalex
- doi:10.1038/srep05959 via openalex
- W6729373804 via openalex
- W6766331743 via openalex
- W6772022409 via openalex
- doi:10.1210/jc.2019-00762 via openalex
- W6789641230 via openalex
- W2995526863 via openalex
- doi:10.1016/j.celrep.2019.11.077 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:02:20.344922+00:00
License: CC0
· commercial use OK